Clinical trials: Patients With Tumor
Breast Cancer, Advanced Breast Cancer
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
- Trial name
- EMBER (NCT04188548)
- Testing
- LY3484356, Abemaciclib, Everolimus
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Stage IV Non-small Cell Lung Cancer
KN046 in Patients With Advanced Non-small Cell Lung Cancer
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
- Trial name
- NCT03838848
- Testing
- KN046, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Tumors
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose)…
- Trial name
- HMPL-504 (NCT01985555)
- Testing
- Volitinib(HMPL-504)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Hutchison Medipharma Limited
Malignant Melanoma
An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
This multi-center, prospective, observational safety study will evaluate the safety and effectiveness of Zelboraf (vemurafenib) in a real world setting.
- Trial name
- NCT01990248
- Where
- 80 sites in Austria, Belgium and 8 more
- Volunteers
- 339 people
- Sponsor
- Hoffmann-La Roche
Tumor Lysis Syndrome, Cancer
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
This is a randomized, multi-center, open-label, parallel group study with three arms: Rasburicase alone Rasburicase followed by Allopurinol Allopurinol alone The primary objective is to compare the adequacy of control of plasma…
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Trial name
- NCT00230178
- Testing
- Rasburicase (SR29142), Allopurinol
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Sanofi
Carcinoma, Large Cell, Neuroendocrine Tumors
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
This is a multi-centric, open-label study evaluating the efficacy and safety of RAD001 in patients with advanced (stage IV) Lung Cancer (Large Cell) with neuroendocrine differentiation treated with a combination of RAD001 with…
- Trial name
- NCT01317615
- Testing
- RAD001, Paclitaxel, Carboplatin
- Where
- 9 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related…
- Trial name
- OPTIMISE (NCT03140176)
- Testing
- Sunitinib
- Where
- 8 sites in Algeria, Egypt and 2 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Cancer, Breast Cancer
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer.
- Trial name
- NCT00082433
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 186 sites in United States, Argentina and 27 more
- Volunteers
- 1,221 people
- Sponsor
- R-Pharm
Breast Cancer
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin in adult patients with triple negative…
- Trial name
- NCT00938652
- Testing
- gemcitabine/carboplatin, Iniparib
- Where
- 102 sites in United States
- Volunteers
- 519 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT04980885
- Testing
- AK117, Azacitidine
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Leukemia
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic…
- Trial name
- NCT00003635
- Testing
- nelarabine
- Where
- 22 sites in United States
- Sponsor
- GlaxoSmithKline
Locally Advanced Metastatic BRAF Mutant Melanoma
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
- Trial name
- NCT01777776
- Testing
- LEE011, LGX818
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Array BioPharma
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.
- Trial name
- NCT02514174
- Testing
- Afatinib
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00391274
- Testing
- pemetrexed, docetaxel
- Where
- 7 sites in China
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Trial name
- KYLIN-2 (NCT06574347)
- Testing
- Vebreltinib, Osimertinib, PLB1004
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Ovarian Cancer Recurrent
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied.
- Trial name
- ESP2011-002 (NCT01485848)
- Testing
- EP-100, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Esperance Pharmaceuticals Inc
Cachexia; Cancer
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients.
- Trial name
- NCT07168226
- Testing
- Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- MetaFines
Melanoma (Skin)
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00003715
- Testing
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- 17 sites in United States
- Volunteers
- 425 people
- Sponsor
- AVAX Technologies
Hematological Disease, Lymphoid Malignancies
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845 is tolerated in patients with haematological diseases and lymphoid malignancies.
- Trial name
- CHR-2845-001 (NCT00820508)
- Testing
- CHR-2845
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 18 people
- Sponsor
- Chroma Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.